News Release

Hackensack Meridian CDI scientists discover new tuberculosis treatment pathway

Peer-Reviewed Publication

Hackensack Meridian Health

CDI Scientists identify TB treatment pathway

image: Dr. Thomas Dick, left, and colleagues at the CDI have identified a new treatment pathway for tuberculosis, a global killer. view more 

Credit: Hackensack Meridian Health

June 29, 2021 - Nutley, NJ - Scientists from the Hackensack Meridian Center for Discovery and Innovation, working with collaborators from across the globe, uncovered the mechanism of action of a novel anti-tuberculosis drug that they have helped develop.

The new findings show how the enzyme inhibitor triaza-coumarin, or TA-C, is metabolized by the TB germs, which makes it effective in inhibiting the disease from within, like in a "Trojan horse" attack, according to the new paper in the journal Proceedings of the National Academy of Sciences.

"This is a promising new direction of research," said Thomas Dick, member of the CDI faculty. "We are hoping this work can make a difference in the ongoing fight against TB."

"The scientists at the CDI who specialize in tuberculosis and other mycobacteria are at the vanguard of their specialty," said David Perlin, PhD., the chief scientific officer and senior vice president of the CDI. "Their promising new lines of research offer hope against a scourge that continues to kill in huge numbers, year after year."

Bacterial metabolism can cause intrinsic drug resistance - but it can also convert inactive parent drugs to bioactive derivatives, as is the case for several antimycobacterial "prodrugs." These "prodrugs" are biologically inactive compounds which are broken down by the bacteria to create the effective byproduct compounds within the bacterial cell.

The scientists show in the paper that intra-bacterial metabolism of TA-C, a new Mycobacterium tuberculosis dihydrofolate reductase (DHFR) inhibitor with moderate affinity for its target, boosts its on-target activity by two orders of magnitude. The TB germ takes up and metabolizes the TA-C - but the byproducts inhibit its function from within.

This is the first 'prodrug-like' antimycobacterial that possesses baseline activity in the absence of intracellular bio-activation. By describing how it works in this latest paper, the authors have provided the foundational basis of a novel class of DHFR inhibitors and uncovered a new antibacterial drug discovery concept.

This new methodology could be crucial in the ongoing fight against TB, which kills 1.3 million people across the globe annually, and which disproportionately afflicts the developing world. New drugs are desperately needed to fight drug-resistant strains of the disease.


The CDI team included Dr. Wassihun Wedajo Aragaw in the Dick lab who uncovered the mechanism of action, as well as colleagues Drs. Veronique Dartois, Martin Gengenbacher and Matthew D. Zimmerman. The international team who collaborated with the CDI included Brendon Lee and Colin Jackson from the Australian National University, and Xuan Yang and Wai-Keung Chui of the National University of Singapore.

Dick and Chui first published a paper in 2017 describing the TA-C compound's apparent effectiveness against TB bacteria.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.